Literature DB >> 2383164

Renal failure in multiple myeloma. Pathogenesis and prognostic implications.

R Alexanian1, B Barlogie, D Dixon.   

Abstract

The pathogenesis, prognosis, and reversibility of renal failure were assessed in 494 consecutive, previously untreated patients with multiple myeloma. For patients with a similar extent of disease, the presence or degree of azotemia did not adversely affect prognosis. Hypercalcemia and/or Bence Jones proteinuria explained the renal failure in 97% of patients. After treatment with a combination of hydration and chemotherapy, normal renal function was achieved in 51% of patients, reversibility usually being rapid and occurring more often in those with slight elevation of serum creatinine. Myeloma control was much more important for survival prolongation than reversal of renal failure, supporting the prompt institution of effective therapy for the underlying malignancy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2383164

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  43 in total

Review 1.  Myeloma light chain cast nephropathy, a review.

Authors:  Insara Jaffer Sathick; Maria Eleni Drosou; Nelson Leung
Journal:  J Nephrol       Date:  2018-05-05       Impact factor: 3.902

Review 2.  Onco-nephrology: AKI in the cancer patient.

Authors:  Albert Q Lam; Benjamin D Humphreys
Journal:  Clin J Am Soc Nephrol       Date:  2012-08-09       Impact factor: 8.237

Review 3.  Atherosclerotic renal artery stenosis: from diagnosis to treatment.

Authors:  P Carmichael; A R Carmichael
Journal:  Postgrad Med J       Date:  1999-09       Impact factor: 2.401

4.  Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.

Authors:  Dao-bin Zhou; Li Yu; Xin Du; Jie Jin; Zhen Cai; Fangping Chen; Xiaoyan Ke; Xiao Li; Depei Wu; Fanyi Meng; Huisheng Ai; Jingshan Zhang; Dena DeMarco; Nianhang Chen; Jay Mei; Jianmin Wang; Jian Hou
Journal:  Int J Hematol       Date:  2015-03-10       Impact factor: 2.490

Review 5.  Novel approaches for reducing free light chains in patients with myeloma kidney.

Authors:  Colin A Hutchison; Joan Bladé; Paul Cockwell; Mark Cook; Mark Drayson; Jean-Paul Fermand; Efstathios Kastritis; Robert Kyle; Nelson Leung; Sonia Pasquali; Christopher Winearls
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

6.  Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases.

Authors:  Nelson Leung; Morie Gertz; Robert A Kyle; Fernando C Fervenza; Maria V Irazabal; Alfonso Eirin; Shaji Kumar; Stephen S Cha; S Vincent Rajkumar; Martha Q Lacy; Steve R Zeldenrust; Francis K Buadi; Suzanne R Hayman; Samih H Nasr; Sanjeev Sethi; Marina Ramirez-Alvarado; Thomas E Witzig; Sandra M Herrmann; Angela Dispenzieri
Journal:  Clin J Am Soc Nephrol       Date:  2012-09-27       Impact factor: 8.237

7.  Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.

Authors:  Katja C Weisel; Meletios A Dimopoulos; Philippe Moreau; Martha Q Lacy; Kevin W Song; Michel Delforge; Lionel Karlin; Hartmut Goldschmidt; Anne Banos; Albert Oriol; Adrian Alegre; Christine Chen; Michele Cavo; Laurent Garderet; Valentina Ivanova; Joaquin Martinez-Lopez; Stefan Knop; Xin Yu; Kevin Hong; Lars Sternas; Christian Jacques; Mohamed H Zaki; Jesus San Miguel
Journal:  Haematologica       Date:  2016-04-14       Impact factor: 9.941

8.  Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan.

Authors:  Masaharu Tamaki; Hideki Nakasone; Ayumi Gomyo; Jin Hayakawa; Yu Akahoshi; Naonori Harada; Machiko Kusuda; Yuko Ishihara; Koji Kawamura; Aki Tanihara; Miki Sato; Kiriko Terasako-Saito; Kazuaki Kameda; Hidenori Wada; Misato Kikuchi; Shun-Ichi Kimura; Shinichi Kako; Yoshinobu Kanda
Journal:  Int J Hematol       Date:  2018-07-23       Impact factor: 2.490

9.  Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.

Authors:  Wolfram Pönisch; Barbara Moll; Malvina Bourgeois; Marc Andrea; Thomas Schliwa; Simone Heyn; Marion Schmalfeld; Thomas Edelmann; Cornelia Becker; Franz Albert Hoffmann; Andreas Schwarzer; Ute Kreibich; Matthias Egert; Runa Stiegler; Rainer Krahl; Yvonne Remane; Anette Bachmann; Tom Lindner; Lorenz Weidhase; Sirak Petros; Stefan Fricke; Vladan Vucinic; Haifa Al Ali; Dietger Niederwieser
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-18       Impact factor: 4.553

10.  Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment.

Authors:  Guangzhong Yang; Wenming Chen; Yin Wu
Journal:  Chin J Cancer Res       Date:  2013-04       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.